Policy & Regulation
Antin to acquire clinical trial equipment provider Emsere
8 January 2026 - Private equity firm Antin Infrastructure Partners (Euronext Paris:ANTIN) announced on Thursday that it has agreed to acquire Emsere from Dutch family investment platform Gryphion.Emse...
Foresee licenses global rights to MMP-12 inhibitor programmes to Primevera
8 January 2026 - Taiwan-based biopharmaceutical company Foresee Pharmaceuticals Co., Ltd. (TPEX: 6576) said on Thursday that it has granted exclusive global rights to its MMP-12 inhibitor programmes t...
Arbele's ARB1002 receives US FDA Orphan Drug Designation
8 January 2026 - Arbele, a Hong Kong-based biotechnology company focused on developing innovative targeted cancer therapies, announced on Wednesday that it has received Orphan Drug Designation (ODD) f...
Sobi reports topline results from Phase 2a EMBRACE study of Gamifant for interferon-gamma-driven sepsis
8 January 2026 - Swedish biopharmaceutical company Sobi (STO:SOBI) on Wednesday reported topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN gamm...
Compass Pathways wins FDA IND acceptance for COMP360 PTSD trial
7 January 2026 - Biotechnology company Compass Pathways plc (Nasdaq: CMPS) announced on Wednesday that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for C...
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
7 January 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, confirmed on Wednesday that it has completed its cash tender offer for all outstanding...